PROGNOSTIC FACTORS OF THE EFFICACY OF ARANOZA-BAZED THERAPY IN NEUROENDOCRINE NEOPLASMS

S. A. Polozkova; Полозкова Светлана Александровна; V. A. Gorbunova; Горбунова В. А.; V. V. Delektorskaya; Делекторская В. В.; N. F. Orel; Орел Н. Ф.; N. N. Kozlov; Козлов Н. Н.; A. E. Kuzminov; Кузьминов А. Е.; A. A. Markovich; Маркович А. А.; A. S. Odintsova; Одинцова А. С.; G. S. Emelyanova; Емельянова Г. С.

doi:10.17650/1726-9784-2017-16-1-38-46

PROGNOSTIC FACTORS OF THE EFFICACY OF ARANOZA-BAZED THERAPY IN NEUROENDOCRINE NEOPLASMS

Authors: Polozkova S.A.¹, Gorbunova V.A.¹, Delektorskaya V.V.¹, Orel N.F.¹^,2, Kozlov N.N.¹, Kuzminov A.E.¹, Markovich A.A.¹, Odintsova A.S.¹, Emelyanova G.S.³
Affiliations:
1. N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
2. Russian Medical Academy of Continuous Education, Ministry of Health of Russiа
3. A.I. Evdokimov Moscow State Medical and Dental University, Ministry of Health of Russia
Issue: Vol 16, No 1 (2017)
Pages: 38-46
Section: ORIGINAL REPORTS
Published: 30.03.2017
URL: https://bioterapevt.abvpress.ru/jour/article/view/853
DOI: https://doi.org/10.17650/1726-9784-2017-16-1-38-46
ID: 853

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Introduction. In patients with neuroendocrine neoplasms it is necessary to search for new prognostic factors to identify a subgroup of patients who will benefit from drug treatment. Aim. The aim of the study was an optimization of Aranoza-based therapy in patients with neuroendocrine neoplasms by using both morphological and clinical factors as predictors of the treatment efficacy. Materials and methods. A total of 122 patients were enrolled and assessed for radiological response (RECIST 1.0) and progression-free survival. Results. Aranoza and its combinations had similar efficacy. The localization of metastases only in the liver, less than 3 metastatic zones, more than 6 courses of Aranoza-bazed chemotherapy, well-differentiated tumors, absence of doses reduction of Aranoza and temozolomide in anamnesis were predictors of the disease control rate. Progression-free survival was higher in patients with disease control rate (objective response + stabilization more than 6 months), Ki-67 < 20 %, well-differentiated tumors, more than 6 courses of Arano-za-based chemotherapy, objective biochemical response, less than 3 metastatic zones and absence of O6-alkylguanine-DNA alkyl-transferase expression. Conclusion. Future analysis of prognostic factors in patients treated with alkylating agents is needed.

Keywords

Араноза, химиотерапия, нейроэндокринные новообразования, прогностические и предиктивные факторы, Aranoza, chemotherapy, neuroendocrine neoplasms, prognostic and predictive factors

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

PROGNOSTIC FACTORS OF THE EFFICACY OF ARANOZA-BAZED THERAPY IN NEUROENDOCRINE NEOPLASMS

Full Text

Abstract

Keywords

About the authors

References

Supplementary files